Shattuck Labs, Inc. 10-K

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities Our common stock is traded on The Nasdaq Global Select Market under the symbol “STTK”. At March 17, 2025, there were approximately 23 stockholders of record of our common stock. Since many of our shares of common stock are held by brokers and other institutions on behalf of stockholders, we are unable to estimate the total number of stockholders represented by these record holders. Dividends The Company has never paid dividends on its Common Stock and does not anticipate that it will do so in the foreseeable future. Use of Proceeds from Initial Public Offering of Common Stock We completed our initial public offering (“IPO”) on October 14, 2020. As a result of the strategic pipeline prioritization and discontinuation of SL-172154, we have changed the “use of proceeds” from the IPO as described in our final prospectus filed with the SEC pursuant to Rule 424(b)(4) on October 13, 2020. We currently expect to use our cash, cash equivalents and investments, which include the remaining net proceeds from our IPO, to advance the preclinical and clinical development of our lead product candidate, SL-325, as well as for general corporate purposes. Recent Sales of Unregistered Securities None. Issuer Purchases of Equity Securities None. Item 6. Reserved